The effect of L-carnitine in non-alcoholic fatty liver disease
Phase 3
Recruiting
- Conditions
- onalcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classified
- Registration Number
- IRCT20240129060837N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 102
Inclusion Criteria
AST, ALT levels above the normal range
Sonographic findings consistent with fatty liver
No history of viral hepatitis or conditions such as hemochromatosis, Wilson’s disease, autoimmune hepatitis, alpha-1 antitrypsin deficiency or chronic liver disease
Exclusion Criteria
Significant alcohol consumption (more than 10 grams per day for women and more than 20 grams per day for men)
Pregnant or breastfeeding women
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decreased level of liver enzymes. Timepoint: Measurement of liver enzymes at the beginning of the study (before the start of the intervention) and 3 months after L-carnitine supplementation. Method of measurement: Check the level of liver enzymes in the serum by the laboratory.;Reducing the amount of liver fat. Timepoint: Measurement of liver enzymes at the beginning of the study (before the start of the intervention) and 3 months after L-carnitine supplementation. Method of measurement: Tansabdominal ultrasound.
- Secondary Outcome Measures
Name Time Method